Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Sea Aktie: Kursziel gesenkt – Shopee wächst, Garena bremst (Aktiencheck) +++ SEA LTD Aktie -3,14%

AZENTA Aktie

 >AZENTA Aktienkurs 
43 EUR    (TradegateBSX)
Ask: 43.2 EUR / 350 Stück
Bid: 42.8 EUR / 360 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
AZENTA Aktie über LYNX handeln
>AZENTA Performance
1 Woche: +9,7%
1 Monat: +7,4%
3 Monate: +25,6%
6 Monate: +122,0%
1 Jahr: +39,6%
laufendes Jahr: +23,1%
>AZENTA Aktie
Name:  AZENTA INC. DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US1143401024 / 257275
Symbol/ Ticker:  BA3 (Frankfurt) / AZTA (NASDAQ)
Kürzel:  FRA:BA3, ETR:BA3, BA3:GR, NASDAQ:AZTA
Index:  -
Profil:  Azenta, Inc. is a life sciences tools and services company focused on sample management, biostorage, and genomic services. The company provides automated storage systems, temperature-controlled logistics, laboratory consumables, informatics, and repo..
>Volltext..
Marktkapitalisierung:  1539.16 Mio. EUR
Unternehmenswert:  1297.15 Mio. EUR
Umsatz:  550.98 Mio. EUR
EBITDA:  35.83 Mio. EUR
Nettogewinn:  -110.32 Mio. EUR
Gewinn je Aktie:  -2.39 EUR
Schulden:  48.44 Mio. EUR
Liquide Mittel:  172.41 Mio. EUR
Operativer Cashflow:  34.09 Mio. EUR
Bargeldquote:  1.2
Umsatzwachstum:  4.66%
Gewinnwachstum:  -13.6%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Div. Historie:  02.12.21 - 0.0858€
02.09.21 - 0.0858€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  AZENTA, BROOKS AUTOMATION
Letzte Datenerhebung:  11.11.26
>AZENTA Kennzahlen
Aktien/ Unternehmen:
Aktien: 43.81 Mio. St.
Frei handelbar: 98.42%
Rückkaufquote: 2.78%
Mitarbeiter: 3000
Umsatz/Mitarb.: 0.18 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 0.93%
Bewertung:
KGV: -
KGV lG: 118.97
KUV: 3.02
KBV: 1.11
PEG-Ratio: -1.61
EV/EBITDA: 36.21
Rentabilität:
Bruttomarge: 44.05%
Gewinnmarge: -18.26%
Operative Marge: -2.57%
Managementeffizenz:
Gesamtkaprendite: -5.75%
Eigenkaprendite: -7.04%
>AZENTA Peer Group
Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Medizinprodukte & -technik/ Implantate/ Wundpflege
 
11.11.26 - 15:48
Azenta übertrifft Q4-Erwartungen deutlich – Aktie springt nachbörslich um 9,6 % an (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
10.11.26 - 22:33
Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026. (PR Newswire)
 
Q4'26 reported revenue growth of 5% year over year and 2% on an organic basis FY'26 reported revenue growth of 5% year over year and 2% on an organic basis FY'27 reported revenue expected to range from $648 to $660 million FY'27 organic revenue growth expected to range between 3% to 5%......
08.11.26 - 19:03
Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA (PR Newswire)
 
NEW YORK, Nov. 8, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Azenta, Inc. (NASDAQ: AZTA) resulting from allegations that Azenta may have issued materially misleading......
03.11.26 - 23:12
Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA (PR Newswire)
 
NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Azenta, Inc. (NASDAQ: AZTA) resulting from allegations that Azenta may have issued materially misleading......
30.10.26 - 13:03
Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities (PR Newswire)
 
Exclusive licensing agreement with Elegen and acquisition of SynPlexity strengthen gene synthesis capabilities, expand high-throughput discovery workflows, and position GENEWIZ for long-term growth BURLINGTON, Mass., Oct. 30, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today......
30.10.26 - 00:25
Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA (PR Newswire)
 
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Azenta, Inc. (NASDAQ: AZTA) resulting from allegations that Azenta may have issued materially misleading......
28.10.26 - 21:09
Azenta Announces Fiscal 2026 Fourth Quarter and Full Year Conference Call and Webcast (PR Newswire)
 
BURLINGTON, Mass., Oct. 28, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2026 earnings which ended on September 30, 2026, on Tuesday, November 10, 2026, after the market closes. The Company will host a conference call and live webcast......
10.10.26 - 18:21
Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA (PR Newswire)
 
NEW YORK, Oct. 10, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Azenta, Inc. (NASDAQ: AZTA) resulting from allegations that Azenta may have issued materially misleading......
07.10.26 - 15:33
Azenta shutting three Multiomics lab sites under restructuring plan (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.10.26 - 03:42
Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA (PR Newswire)
 
NEW YORK, Oct. 5, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Azenta, Inc. (NASDAQ: AZTA) resulting from allegations that Azenta may have issued materially misleading......
29.09.26 - 03:24
Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA (PR Newswire)
 
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Azenta, Inc. (NASDAQ: AZTA) resulting from allegations that Azenta may have issued materially misleading......
10.09.26 - 17:06
Brooks Automation Files Confidentially for IPO (WSJ EN)
 
Private-equity firm THL owns the company....
04.09.26 - 16:45
Azenta completes B Medical divestiture as Thelema repays vendor loan (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.09.26 - 14:03
Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems (PR Newswire)
 
BURLINGTON, Mass., Sept. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has received repayment in full, prior to maturity, of the $35 million secured vendor loan extended in connection with the previously announced sale of B Medical Systems S.à r.l. to Thelema......
03.09.26 - 16:18
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA (PR Newswire)
 
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation......
27.08.26 - 22:39
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA (PR Newswire)
 
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation......
24.08.26 - 22:21
Azenta tumbles 12% after CEO transition (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
24.08.26 - 17:36
Warum die Azenta Aktie heute fällt (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
24.08.26 - 14:18
Azenta appoints board member Martin Madaus interim CEO as John Marotta exits (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
24.08.26 - 14:03
AZENTA ANNOUNCES LEADERSHIP TRANSITION (PR Newswire)
 
Current Director Dr. Martin Madaus Appointed Interim CEO Company Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue Guidance BURLINGTON, Mass., Aug. 24, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company") today announced that current member of......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ein Schriftsteller kann die Welt im besten Fall beunruhigen, im seltensten Fall beeinflussen - verändern nie. - Friedrich Dürrenmatt
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!